LivaNova PLC and Orrum Clinical Analytics have announced a partnership that will connect LivaNova’s Essenz™ Perfusion System to Orrum’s CŌRE Insights™ analytics platform, enabling automatic transfer of performance data from the heart‑lung machines into Orrum’s secure, legally privileged Patient Safety Organization environment. The integration will give clinicians real‑time access to benchmarking and actionable insights that can improve patient outcomes and operational efficiency.
The collaboration will allow performance data from LivaNova’s heart‑lung machines to flow into Orrum’s analytics tools, providing hospitals with peer benchmarking and data‑driven decision support for open‑heart procedures. By combining advanced hardware with actionable data, the partnership aims to strengthen the Essenz platform’s value proposition and differentiate it in the cardiopulmonary market.
Orrum CEO Sean Murtha said the collaboration is rooted in a shared objective to empower clinicians and elevate patient outcomes, and that the partnership will usher in a new era of analytics in cardiac surgery. LivaNova has not yet issued a statement, but the move follows the company’s recent regulatory approvals for the Essenz system, including FDA 510(k) clearance in March 2023 and NMPA approval in China in August 2025.
The partnership comes ahead of LivaNova’s fourth‑quarter and full‑year 2025 earnings release scheduled for February 25, 2026, and is expected to enhance the value proposition of the Essenz platform, potentially driving future adoption and revenue growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.